gov identifier: NCT00849056, NCT00849017, NCT00838903, NCT00838916, and NCT00839527) evaluated the efficacy and safety of a once-weekly administration of Albiglutide in 4838 patients with T2DM [35] showing additional significant data on cardiovascular safety and benefit within the GLP-1 analogue/agonist class. Here, GLP1R is linked to type 2 diabetes mellitus.